Administered by trained personnel using a calibrated vaporizer specifically designed for Isoflurane, as part of an inhalation anesthetic delivery system. Requires continuous monitoring of patient vital signs and anesthetic depth.

Isoflurane acts as a general anesthetic by modulating several ion channels, enhancing GABAergic inhibitory neurotransmission, and reducing excitatory neurotransmission in the central nervous system.

• •Known hypersensitivity to Isoflurane or other halogenated agents.
• •Known or suspected genetic susceptibility to malignant hyperthermia.
• •History of hepatic dysfunction or jaundice following prior halogenated anesthetic administration.
• •Uncontrolled intracranial pressure where a further increase would be hazardous.

Store at room temperature (15°C to 30°C / 59°F to 86°F). Protect from light. Keep container tightly closed when not in use. Do not freeze.

Overdose manifests as profound hypotension and respiratory depression, potentially leading to cardiac arrest. Management involves immediately discontinuing administration, ensuring a patent airway, initiating assisted or controlled ventilation with oxygen, and providing cardiovascular support.

Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Small amounts may be excreted in breast milk; caution is advised for nursing mothers.